Why Manufacturer Interest Is Accelerating
The conditions for manufacturer direct-to-employer pharmacy programs have never been stronger. The Consolidated Appropriations Act now classifies PBMs as covered service providers under ERISA, requiring full compensation disclosure and rebate pass-through. Congressional hearings have placed PBM economics on the public record. GLP-1 medications have pushed specialty drug spend to a level where employers are actively seeking alternatives to the traditional distribution chain. And self-funded employers, who bear the actual cost of their members' drug benefits, are asking for manufacturer-direct drug pricing with increasing urgency.
Manufacturers are paying attention. Several have launched patient-facing programs. Others have explored partnerships with specialty pharmacies or benefit navigators. But the structural opportunity is larger than any single patient access initiative. The manufacturers who build or access direct-to-employer pharmacy infrastructure now will have a measurable advantage as the market shifts. Those who wait will find the channel defined by others.
The Gap Between Intent and Execution
Most pharmaceutical manufacturers already have some form of patient access infrastructure. Copay assistance programs, hub services, patient support portals, and free drug programs are standard across the industry. These programs serve an important purpose, but none of them constitute a direct-to-employer channel.
A DTE channel is structurally different. It means the manufacturer's pricing is available inside the employer's benefit plan. The prescription is adjudicated in real time. The member's cost share applies to their deductible and out-of-pocket maximum. The employer is the contracting party, and the transaction appears in the employer's claims data alongside every other covered prescription.
This is not a patient assistance workaround or a coupon program layered on top of an existing PBM benefit. It is a parallel supply pathway that operates within the benefit, with the employer's knowledge and contractual authorization. The operational requirements to make this work are fundamentally different from anything in a manufacturer's current patient access toolkit.
What a DTE Channel Actually Requires
A functioning direct-to-employer pharmacy program requires a complete operational stack. Each component must work in coordination with the others, and a gap in any single area means the program cannot operate inside a benefit plan.
The process begins with electronic prescription intake. Prescriptions must arrive through standard NCPDP SCRIPT workflows so that prescribers do not need to change their behavior or use a separate system. If the intake pathway requires manual intervention or a nonstandard workflow, prescriber adoption will be minimal and the channel will not scale.
Once a prescription arrives, the system must verify the member's eligibility against the employer's covered population in real time. This is not a simple database lookup. It requires an active connection to the employer's eligibility feed, updated regularly, so that only enrolled members with qualifying prescriptions enter the program.
The next layer is the program rules engine. Each employer configures its own parameters: member cost share amounts, prior authorization or utilization management criteria, and conversion logic for prescriptions that may qualify for the manufacturer-direct channel but are initially written for a PBM-adjudicated pathway. These rules must be applied automatically at the point of decision, not reviewed manually after the fact.
With eligibility confirmed and rules applied, the system must evaluate the prescription against all available fulfillment channels in real time. This means comparing the manufacturer-direct price against the PBM's standard pricing, retail pharmacy pricing, and any other activated supply paths. The routing decision must select the lowest net cost option and document the comparison. If the manufacturer-direct channel is not the lowest cost for a given prescription, the prescription should route elsewhere. This is what makes the program credible to employers and their fiduciary advisors.
Fulfillment requires a licensed pharmacy of record to dispense the medication. The dispensing pharmacy must be credentialed, and the fulfillment process must comply with all state and federal pharmacy regulations. For serialized products, DSCSA compliance is mandatory. This means generating per-prescription T3 documentation that traces the product from the manufacturer through custody and dispensing. In a DTE model where the manufacturer ships to a third-party logistics provider rather than a traditional wholesaler, meeting DSCSA requirements is a significant technical challenge that requires purpose-built infrastructure.
After dispensing, the system must submit a claim to the employer's third-party administrator. This can be a medical claim or a pharmacy claim, depending on the employer's benefit design. Claim submission ensures that the transaction appears in the employer's claims data and that the member's cost share counts toward their deductible and accumulators. Without this step, the prescription sits outside the benefit, which defeats the purpose of a DTE program.
Financial settlement is the final operational requirement. The platform must collect the member's cost share, pay the dispensing pharmacy, and settle with the manufacturer, typically via ACH on a monthly cycle. And every prescription must generate a decision-level record that documents the channels compared, the rules applied, the routing rationale, and the net cost components. This record is what allows the employer to demonstrate fiduciary prudence under ERISA and the Consolidated Appropriations Act.
Missing any one of these components means the program cannot run as a covered benefit. It may function as a patient access program or a discount card, but it will not operate inside the employer's plan with the compliance, documentation, and data integration that employers require.
The Build vs. Partner Question
Given the complexity of the operational stack, most manufacturers should not attempt to build this pharmacy benefit infrastructure internally. Pharmacy licensure, DSCSA compliance systems, employer contracting, TPA integration, and real-time routing engines are not core manufacturer competencies. The regulatory surface area is large, the implementation timeline is two to three years at minimum, and the ongoing operational burden is significant.
The more practical path is partnering with a platform that already has these components built and operational. When evaluating a partner, manufacturers should look for several specific capabilities. The platform must hold pharmacy licensure, because the DTE model requires a licensed entity to process and route prescriptions. It should have no ownership stake in any dispensing channel, because structural independence is what makes the routing decision credible to employers and their consultants. It must have a demonstrated DSCSA compliance capability, particularly for the custody-without-title model that DTE programs typically require. It should have existing employer relationships and contracting infrastructure, so the manufacturer is not building demand from scratch. And it must produce decision-level documentation for every prescription, because that is the evidentiary standard that employers and their legal counsel now expect.
Channel Preservation
A common concern among manufacturer commercial and legal teams is that launching a direct-to-employer channel will conflict with existing PBM contracts or distributor relationships. This concern is legitimate but addressable through the right infrastructure architecture.
In a properly structured DTE program, the manufacturer's only counterparty is the infrastructure platform. The manufacturer does not contract with individual employers. Employer demand is transmitted through the platform as the authorized channel operator, similar to how PBM contracts already contemplate intermediary relationships. The manufacturer's existing wholesaler and distributor arrangements remain intact, because the DTE channel uses a separate supply pathway that does not displace traditional distribution volume for the broader formulary.
PBM relationships are preserved because the DTE channel operates as a parallel pathway alongside the employer's existing PBM benefit. The PBM continues to administer the broad formulary. The DTE channel handles only the specific high-cost drugs that the employer has configured for the program. When the routing engine determines that the PBM channel is the lowest net cost option for a given prescription, the prescription stays with the PBM. The two channels coexist by design.
WAC is preserved across all channels in a DTE model. The manufacturer-direct pricing is structured as a program rebate applied as a line deduction on the monthly invoice, which avoids triggering most-favored-nation provisions that are typically calculated against WAC. Manufacturer legal teams should validate the specific MFN language in their contracts, but the structure is designed to maintain compliance.
What Manufacturers Gain
The DTE channel offers several advantages that no other distribution model provides. The manufacturer maintains pricing control to the point of dispense, with no intermediary margin or opaque spread between the contracted price and what the employer actually pays. Rebates are applied at dispense rather than held for 90 to 180 days by intermediaries. The manufacturer receives real-time member-level data, including dispense events, adherence metrics, and prescriber attribution, which the traditional distributor channel structurally cannot provide because it reports sell-in rather than sell-through.
The employer's formulary commitment is documented and locked for the program's duration, giving the manufacturer a stable commercial position that is not subject to mid-year formulary changes driven by PBM rebate negotiations. And every routing decision is supported by a decision-level record proving that the manufacturer-direct channel was selected on merit, based on a real-time comparison against all available alternatives. This is the kind of documentation that supports the manufacturer's value proposition to employers and removes the perception that DTE is simply a way to circumvent the PBM.
The Infrastructure Exists Today
The operational requirements for a manufacturer direct-to-employer drug program are significant, but the pharmacy benefit infrastructure to meet them is already built. ApalyRx provides the complete operating layer for DTE programs: eRx intake, eligibility, DSCSA compliance, multi-channel routing, fulfillment, settlement, and decision-level documentation for every prescription. The platform is operational today with Fortune 500 employer clients. For manufacturers ready to activate a direct-to-employer channel, learn how the infrastructure works.